Abstract
A 71 years old female patient with sigmoid cancer complained of rapidly growing meteorism, abdominal pain and tarry stool and was proved to have acquired factor V inhibitor producibility together with severe anemia, depression of platelet aggregability and marked prolongation of Stypven time. This inhibitor was revealed to belong to IgG which showed its inhibitor activity on factor V in normal plasma rather slowly and diminished by a factor VIII inhibitor bypassing activity preparation from blood: FEIBA in vivo as well as in vitro.
She was administered FEIBA intravenously and her hemorrhage cured remarkably for some while, but she expired soon when melena and the other hemorrhagic symptoms reoccurred to put her in hemorrhagic shock state.
The action of FEIBA was prominently strengthened by the addition of phospholipid with tissue thromboplastin component and calcium ion; so thus prudent control of the phospholipid level in plasma at the clinical application of this preparation was evaluated to bring good clinical effect and to avoid serious side effects such as hemorrhage, shock, defibrination syndrome, etc.
